Complete Filing Data
CollPlant Biotechnologies Ltd reported Research And Development Expense of $8.19 million for FY2025.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean CollPlant Biotechnologies Ltd did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income * | -$11.5M | -$16.6M | -$7.0M | -$16.9M | $237.0K | -$5.8M | -$11.2M | -$6.2M | -$6.1M | -$27.9M | -$18.7M |
| Research And Development Expense | $8.2M | $10.5M | $10.5M | $10.3M | $7.6M | $4.1M | $4.4M | $3.9M | $584.0K | $29.2M | $22.9M |
| Gross Profit | $1.5M | -$1.1M | $9.0M | -$101.0K | $13.6M | $3.1M | $439.0K | $3.4M | $415.0K | $292.0K | |
| Revenues | $2.4M | $515.0K | $11.0M | $299.0K | $15.6M | $6.1M | $2.3M | $5.0M | |||
| Operating Income Loss | -$11.5M | -$17.3M | -$7.5M | -$17.1M | $65.0K | -$5.6M | -$7.6M | -$4.2M | |||
| General And Administrative Expense | $4.8M | $5.6M | $6.0M | $6.7M | $5.9M | $4.7M | $3.7M | $3.7M | |||
| Cost Of Revenue | $835.0K | $1.6M | $2.0M | $400.0K | $2.0M | $3.0M | $1.9M | $1.7M | |||
| Nonoperating Income Expense | -$6.0K | $642.0K | $493.0K | $172.0K | $172.0K | -$175.0K | -$3.5M | ||||
| Selling General And Administrative Expense | $3.7M | $3.7M | $2.5M | $11.0M | $7.0M | ||||||
| Profit Loss From Operating Activities | -$7.6M | -$4.2M | -$6.0M | -$27.5M | -$18.8M | ||||||
| Comprehensive Income | -$11.2M | -$6.8M | -$5.8M | -$27.9M | -$18.7M | ||||||
| Revenue | $2.4M | $515.0K | $11.0M | $299.0K | $15.6M | $6.1M | $2.3M | $5.0M | |||
| Cost Of Sales | $1.9M | $1.7M | $48.0K | ||||||||
| Adjustments For Reconcile Profit Loss | $247.0K | $1.1M | -$141.0K | $3.9M | -$611.0K |
Balance Sheet
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stockholders Equity | $6.1M | $13.5M | $28.3M | $32.3M | $45.1M | $4.5M | $4.1M | $5.4M | $5.2M | |||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $5.6M | $11.9M | $26.7M | $29.9M | $13.4M | $3.5M | $4.0M | $5.7M | $5.3M | |||
| Liabilities | $4.7M | $5.2M | $5.8M | $5.5M | $6.1M | $6.4M | $6.7M | $3.3M | $19.0M | $9.3M | ||
| Assets | $10.8M | $18.7M | $34.1M | $37.8M | $51.2M | $10.8M | $10.8M | $8.8M | $28.0M | $14.4M | ||
| Cash And Cash Equivalents At Carrying Value | $5.6M | $11.9M | $26.7M | $29.7M | $13.1M | $3.3M | $3.8M | $5.4M | ||||
| Right Of Use Asset Obtained In Exchange For Operating Lease Liability | $101.0K | $572.0K | $886.0K | $219.0K | $557.0K | $23.0K | $97.0K | |||||
| Equity | $6.1M | $13.5M | $28.3M | $32.3M | $45.1M | $4.5M | $4.1M | $5.4M | $5.2M | |||
| Cash And Cash Equivalents | $3.8M | $5.4M | $4.8M | $3.8M | $5.3M | $11.1M | ||||||
| Retained Earnings Accumulated Deficit | -$124.8M | -$113.4M | -$96.7M | -$89.7M | -$72.8M | -$73.0M | -$67.3M | |||||
| Property Plant And Equipment Net | $1.5M | $2.3M | $2.8M | $3.0M | $2.7M | $2.1M | $2.3M | |||||
| Prepaid Expense And Other Assets Current | $223.0K | $433.0K | $393.0K | $543.0K | $424.0K | $239.0K | $270.0K | |||||
| Operating Lease Right Of Use Asset | $2.4M | $3.0M | $3.1M | $2.7M | $3.0M | $2.8M | $3.2M | |||||
| Operating Lease Liability Noncurrent | $2.0M | $2.3M | $2.5M | $2.4M | $3.1M | $2.9M | $3.1M | |||||
| Operating Lease Liability Current | $814.0K | $806.0K | $624.0K | $529.0K | $519.0K | $440.0K | $455.0K | |||||
| Liabilities Noncurrent | $2.0M | $2.3M | $2.5M | $2.4M | $3.1M | $3.0M | $3.2M | |||||
| Liabilities Current | $2.7M | $3.0M | $3.3M | $3.1M | $3.0M | $3.4M | $3.5M | |||||
| Liabilities And Stockholders Equity | $10.8M | $18.7M | $34.1M | $37.8M | $51.2M | $10.8M | $10.8M | |||||
| Inventory Net | $573.0K | $440.0K | $714.0K | $1.4M | $1.1M | $1.3M | $888.0K | |||||
| Common Stock Value | $5.5M | $5.0M | $5.0M | $4.9M | $4.7M | $2.9M | $2.4M | |||||
| Assets Noncurrent | $4.0M | $5.5M | $6.1M | $6.1M | $6.1M | $5.2M | $5.7M | |||||
| Assets Current | $6.7M | $13.2M | $28.0M | $31.7M | $45.1M | $5.7M | $5.0M | |||||
| Accrued Liabilities And Other Liabilities | $1.2M | $1.3M | $1.6M | $1.4M | $1.4M | $1.9M | $1.2M | |||||
| Accounts Payable Trade Current | $610.0K | $870.0K | $980.0K | $1.1M | $1.0M | $798.0K | $833.0K | |||||
| Intangible Assets Net Excluding Goodwill | $73.0K | $131.0K | $188.0K | $245.0K | $243.0K | $82.0K | ||||||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | -$6.3M | -$14.8M | -$3.2M | $16.5M | $9.8M | -$445.0K | ||||||
| Purchase Of Property Plant And Equipment Classified As Investing Activities | $1.5M | $832.0K | $127.0K | $492.0K | $1.4M | |||||||
| Cash Flows From Used In Investing Activities | -$1.5M | -$832.0K | -$127.0K | -$492.0K | -$1.4M | |||||||
| Cash Flows From Used In Financing Activities | $5.4M | $2.8M | $9.1M | $18.5M | $10.0M | |||||||
| Accounts Receivable Net Current | $1.0K | $150.0K | $9.0K | $270.0K | $830.0K | $79.0K | ||||||
| Property Plant And Equipment | $2.3M | $1.4M | $3.6M | $4.0M | $2.6M |
Cash Flow Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Share-Based Compensation * | $999.0K | $1.7M | $1.9M | $2.2M | $1.6M | $1.7M | $1.1M | $1.4M | |||
| Payments To Acquire Property Plant And Equipment | $28.0K | $483.0K | $954.0K | $1.3M | $1.4M | $437.0K | $1.5M | $832.0K | |||
| Net Cash Provided By Used In Investing Activities | -$27.0K | -$539.0K | -$1.2M | $28.9M | -$31.6M | -$519.0K | -$1.5M | -$832.0K | |||
| Net Cash Provided By Used In Financing Activities | $3.1M | $9.0K | $1.1M | $1.9M | $38.8M | $4.5M | $5.4M | $2.8M | |||
| Increase Decrease In Inventories | $129.0K | -$280.0K | -$749.0K | $312.0K | -$181.0K | $374.0K | $74.0K | $653.0K | |||
| Increase Decrease In Accounts Payable Trade | -$260.0K | -$110.0K | -$153.0K | $99.0K | $236.0K | -$35.0K | $228.0K | -$112.0K | |||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $26.0K | -$142.0K | -$379.0K | -$608.0K | $143.0K | $60.0K | -$62.0K | -$325.0K | |||
| Net Cash Provided By Used In Operating Activities | -$9.4M | -$14.1M | -$2.8M | -$13.7M | $2.5M | -$4.5M | -$5.7M | -$1.2M | |||
| Increase Decrease In Other Accounts Payable And Accrued Liabilities | -$46.0K | -$353.0K | $204.0K | $14.0K | -$464.0K | $740.0K | $629.0K | $99.0K | |||
| Increase Decrease In Accounts Receivable | -$149.0K | $150.0K | -$9.0K | -$261.0K | -$560.0K | $751.0K | -$437.0K | $439.0K | |||
| Effect Of Exchange Rate Changes On Cash And Cash Equivalent | -$379.0K | -$608.0K | $143.0K | $60.0K | $62.0K | $184.0K | $28.0K | $157.0K | |||
| Increase Decrease In Operating Lease Liability | -$336.0K | -$650.0K | -$638.0K | -$916.0K | -$337.0K | -$229.0K | $145.0K | ||||
| Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition | $1.0M | $1.7M | $2.0M | $2.2M | $1.6M | ||||||
| Increase Decrease In Deferred Revenue | -$32.0K | -$175.0K | -$735.0K | -$1.0M | $2.0M | ||||||
| Increase Decrease In Cash And Cash Equivalents | -$1.8M | $704.0K | $4.0M | -$1.4M | -$5.8M | ||||||
| Effect Of Exchange Rate Changes On Cash And Cash Equivalents | $62.0K | -$325.0K | $139.0K | -$157.0K | -$104.0K | ||||||
| Proceeds From Issuing Shares | 5.4M | 2.8M | 8.2M | 18.5M | 10.0M | ||||||
| Increase Decrease In Other Receivables | $119.0K | $185.0K | -$31.0K | -$35.0K | -$220.0K | ||||||
| Increase Decrease In Other Operating Assets | -$666.0K | -$651.0K | -$527.0K | -$461.0K | -$400.0K |
Per-Share & Share Counts
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Diluted EPS * | -$0.94 | -$1.45 | -$0.62 | -$1.53 | $0.02 | -$0.84 | -$2.23 | $1.43 | |||
| Weighted Average Number Of Shares Outstanding Basic | 12.2M | 11.5M | 11.4M | 11.0M | 10.0M | 6.9M | 5.0M | ||||
| Weighted Average Number Of Diluted Shares Outstanding | 12.2M | 11.5M | 11.4M | 11.0M | 12.0M | 6.9M | 5.0M | ||||
| Earnings Per Share Basic | $-0.94 | $-1.45 | $-0.62 | $-1.53 | $0.02 | $-0.84 | $-2.23 | ||||
| Common Stock Shares Authorized | 30.0M | 30.0M | 30.0M | 30.0M | 30.0M | 30.0M | 30.0M | ||||
| Common Stock Shares Outstanding | 12.8M | 11.5M | 11.5M | 11.2M | 10.8M | 7.0M | 5.7M | ||||
| Common Stock Shares Issued | 12.8M | 11.5M | 11.5M | 11.2M | 11.2M | 7.0M | 5.7M | ||||
| Common Stock Par Or Stated Value Per Share | $1.50 | $1.50 | $1.50 | $1.50 | $1.50 | $1.50 | $1.50 | ||||
| Basic And Diluted Earnings Loss Per Share | $2.23 | $1.43 | $2.27 | $0.28 | $0.22 | ||||||
| Weighted Average Shares | 5.0M | 4.4M | 2.7M | 100.6M | 84.7M |
Other Metrics
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Stock Issued During Period Value Stock Options Exercised | $9.0K | $364.0K | $174.0K | $299.0K | $89.0K | $7.0K | ||||
| Finance Income Cost | -$3.5M | -$2.0M | -$94.0K | -$348.0K | $164.0K | |||||
| Finance Costs | $3.3M | $2.2M | $47.0K | $441.0K | $51.0K | |||||
| Increase Decrease Through Sharebased Payment Transactions | $1.1M | $1.0M | $531.0K | $3.6M | $4.1M | |||||
| Adjustments For Sharebased Payments | $1.1M | $1.4M | $956.0K | $3.6M | $4.1M | |||||
| Adjustments For Depreciation And Amortisation Expense | $539.0K | $342.0K | $230.0K | $864.0K | $788.0K | |||||
| Finance Income | $1.7M | $253.0K | $93.0K | $215.0K |
Most recent annual filing with the SEC: March 26, 2026
Data sourced from SEC EDGAR public filings as of August 5, 2026.